Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205-502, a new dopamine agonist mainly stimulating D2 receptors

Background and aims. Acromegaly is a complex endocrine disorder caused by excessive secretion of GH, secondary to a GH secreting pituitary adenoma or a mixed pituitary adenoma secreting GH and PRL.Methods. The aim of this study was to evaluate the effects of combination therapy: dopamine agonist and somatostatin analogue on GH and IGF1 levels in a group of 30 patients with acromegaly. Cabergoline in a dose of 2 mg/week and 4 mg/week respectively was associated with Sandostatin LAR in a dose of 20 mg/month and 30 mg/months respectively. Eight patients were treated with Lanreotide 30 mg/week and Cabergoline 2 mg/week and 3 patients were treated with Bromocriptine 10 mg/day and Sandostatin LAR 30 mg/month.Results. Combination therapy: Cabergoline and Sandostatin achieved normal levels of IGF1 in 32% of the patients, better results being obtained after 12 months of treatment in the group treated with 4 mg Cabergoline/week. In 37% of cases the levels of IGF1 decreased by 50% after 12 months of treatment. In the group treated with Cabergoline and Somatuline a normal level of IGF1 was achieved in 25% of patients after 12 months of treatment. The outcome for the group treated with Sandostatin and Bromocriptine was similar to that obtained under Cabergoline 2 mg/week. There was no significant correlation between the level of GH and the type or dose of dopamine agonist used.Conclusions. In conclusion, combination therapy consisting of dopamine agonist and somatostatin analogue achieves a significant reduction of IGF1 levels in patients with mixed adenomas secreting GH and PRL. A decrease in IGF1 levels is directly correlated with the dose of Cabergoline used.

Download Full-text

MPTH-07. ROLE OF CELL-CYCLE REGULATORS IN PREDICTING PROGRESSION OF SILENT PITUITARY ADENOMA AFTER SURGICAL RESECTION

Neuro-Oncology ◽

10.1093/neuonc/now212.445 ◽

2016 ◽

Vol 18 (suppl_6) ◽

pp. vi106-vi107

Author(s):

Sung Hyun Park ◽

JI Hwan Jang

Keyword(s):

Cell Cycle ◽

Pituitary Adenoma ◽

Surgical Resection ◽

Cell Cycle Regulators ◽

Silent Pituitary Adenoma

Download Full-text

DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma

Cancer Letters ◽

10.1016/j.canlet.2019.05.043 ◽

2019 ◽

Vol 459 ◽

pp. 135-144 ◽

Cited By ~ 2

Author(s):

Hong Yao ◽

Hao Tang ◽

Yong Zhang ◽

Qiu Fen Zhang ◽

Xin Yi Liu ◽

...

Keyword(s):

Cell Proliferation ◽

Pituitary Adenoma ◽

Dopamine Agonist

Download Full-text

(−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors

Nuclear Medicine and Biology ◽

10.1016/s0969-8051(00)00144-x ◽

2000 ◽

Vol 27 (6) ◽

pp. 533-539 ◽

Cited By ~ 60

Author(s):

Dah-Ren Hwang ◽

Lawrence S Kegeles ◽

Marc Laruelle

Keyword(s):

Dopamine Agonist ◽

Pet Imaging ◽

D2 Receptors

Download Full-text

Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia

Endocrine Journal ◽

10.1507/endocrj.ej20-0185 ◽

2020 ◽

Author(s):

Natsuki Baba ◽

Hiraku Kameda ◽

Akinobu Nakamura ◽

Kyu Yong Cho ◽

Hiroshi Nomoto ◽

...

Keyword(s):

Pituitary Adenoma ◽

Glucose Tolerance ◽

Metabolic Disorders ◽

Abnormal Glucose Tolerance ◽

Silent Pituitary Adenoma

Download Full-text

The Importance of Immunohistochemical Analysis in Silent Pituitary Adenoma

Medicinus ◽

10.19166/med.v6i3.1150 ◽

2018 ◽

Vol 6 (3) ◽

Author(s):

Ivan William Harsono ◽

Nathania Victoria Stevina ◽

Vivien Puspitasari ◽

Julius July

Keyword(s):

Pituitary Adenoma ◽

Immunohistochemical Analysis ◽

Mass Effect ◽

Visual Disturbance ◽

Neurological Deficits ◽

Parasellar Region ◽

Benign Nature ◽

Silent Pituitary Adenoma ◽

Sinus Cavernosus ◽

Benign Course

Pituitary adenoma contributes to 15% of all intracranial neoplasm. It is usually following benign course and some of them are silent (asymptomatic clinically, but hormone-secreting). Silent adenoma usually found incidentally or when the patients show mass effect (neurological deficits). Many of histologically aggressive silent adenoma subtypes are associated with invasiveness, recurrence and progression to clinically functioning adenomas. Aggressive silent adenoma radiologically tends to invade in downward direction, invading bone, sinus cavernosus, parasellar region. The nature of aggressive silent adenoma subtypes is differing in nature compared to benign nature of pituitary adenoma and should be confirmed immunohistochemically to determine the prognosis and anticipate the risk of recurrence or progression. The case illustration show a real case of 46 years old female progressive headache and visual disturbance diagnosed with non-functional pituitary macroadenoma but positive for more than one immunochemistry biomarker (plurihormonal aggressive silent adenoma).

Download Full-text